Abstract
The ubiquitin-proteasome pathway (UPP) is the major non-lysosomal proteolytic system in the cytosol and nucleus of all eukaryotic cells. Bortezomib (also known as PS-341 and Velcade™) is a proteasome inhibitor, a novel class of cancer therapies. Bortezomib blocks multi-ubiquitinated protein degradation by inhibiting 26S proteasome activity, including regulating cell cycle, anti-apoptosis, and inflammation, as well as immune surveillance. In multiple myeloma (MM) cells, bortezomib directly induces cell stress response followed by activation of c-Jun NH2 terminal kinase (JNK)/stress-activated protein kinase (SAPK), and triggers caspase-dependent apoptosis of tumor cells. Recent clinical studies demonstrated that bortezomib had remarkable anti-tumor activity in refractory and relapsed MM, providing the basis to approval by FDA. Its anti-tumor activities earlier in the course, in combination therapies, and in other malignancies is ongoing.
Keywords: Apoptosis, Cell Adhesion, Cytokine, Proteasome inhibitors, Anti-Angiogenesis, Multiple Myeloma (MM)
Current Pharmaceutical Biotechnology
Title: Bortezomib as an Antitumor Agent
Volume: 7 Issue: 6
Author(s): A. M. Roccaro, T. Hideshima, P. G. Richardson, D. Russo, D. Ribatti, A. Vacca, F. Dammacco and K. C. Anderson
Affiliation:
Keywords: Apoptosis, Cell Adhesion, Cytokine, Proteasome inhibitors, Anti-Angiogenesis, Multiple Myeloma (MM)
Abstract: The ubiquitin-proteasome pathway (UPP) is the major non-lysosomal proteolytic system in the cytosol and nucleus of all eukaryotic cells. Bortezomib (also known as PS-341 and Velcade™) is a proteasome inhibitor, a novel class of cancer therapies. Bortezomib blocks multi-ubiquitinated protein degradation by inhibiting 26S proteasome activity, including regulating cell cycle, anti-apoptosis, and inflammation, as well as immune surveillance. In multiple myeloma (MM) cells, bortezomib directly induces cell stress response followed by activation of c-Jun NH2 terminal kinase (JNK)/stress-activated protein kinase (SAPK), and triggers caspase-dependent apoptosis of tumor cells. Recent clinical studies demonstrated that bortezomib had remarkable anti-tumor activity in refractory and relapsed MM, providing the basis to approval by FDA. Its anti-tumor activities earlier in the course, in combination therapies, and in other malignancies is ongoing.
Export Options
About this article
Cite this article as:
Roccaro M. A., Hideshima T., Richardson G. P., Russo D., Ribatti D., Vacca A., Dammacco F. and Anderson C. K., Bortezomib as an Antitumor Agent, Current Pharmaceutical Biotechnology 2006; 7 (6) . https://dx.doi.org/10.2174/138920106779116865
DOI https://dx.doi.org/10.2174/138920106779116865 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potential Gene Therapy Strategies for Cancer Stem Cells
Current Gene Therapy Transcriptional Regulation of mPGES1 in Cancer: An Alternative Approach to Drug Discovery?
Current Drug Targets Molecular Modeling Studies of ABC Transporters Involved in Multidrug Resistance
Mini-Reviews in Medicinal Chemistry Modulation of Carbonic Anhydrase 9 (CA9) in Human Brain Cancer
Current Pharmaceutical Design Cancer Pharmacogenomics: Germline DNA, Tumor DNA, or Both?
Current Pharmacogenomics A Qualitative and Quantitative Study of the Innervation of the Human Non Pregnant Uterus
Current Protein & Peptide Science Isoprenylation of Intracellular Proteins as a New Target for the Therapy of Human Neoplasms: Preclinical and Clinical Implications
Current Drug Targets Chromatin Remodeling Agents for Cancer Therapy
Reviews on Recent Clinical Trials Retinoids as Differentiating Agents in Oncology: A Network of Interactions with Intracellular Pathways as the Basis for Rational Therapeutic Combinations
Current Pharmaceutical Design Understanding Healthy Protective Mechanisms Against Old Age
Current Aging Science Use of Metallomics in Environmental Pollution Assessment Using Mice Mus musculus/Mus spretus as Bioindicators
Current Analytical Chemistry Beyond PD-1/PD-L1 Axis Blockade: New Combination Strategies in Metastatic Melanoma Treatment
Current Cancer Therapy Reviews Role of mTOR in Hematological Malignancies
Current Cancer Therapy Reviews Cruciferous Plants: Phytochemical Toxicity Versus Cancer Chemoprotection
Mini-Reviews in Medicinal Chemistry Study of drug-drug combinations based on molecular descriptors and physicochemical properties
Combinatorial Chemistry & High Throughput Screening Metallic Colloid Nanotechnology, Applications in Diagnosis and Therapeutics
Current Pharmaceutical Design Epithelial Mesenchymal Transition in Cancer Progression: Prev entive Phytochemicals
Recent Patents on Anti-Cancer Drug Discovery Potential Novel Treatments for Bipolar Depression: Ketamine, Fatty Acids, Anti-inflammatory Agents, and Probiotics
CNS & Neurological Disorders - Drug Targets Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery The Potential Application of Biomaterials in Cardiac Stem Cell Therapy
Current Medicinal Chemistry